[Preclinical pharmacological profiles and clinical outcome of the novel melatonin-receptor agonist ramelteon (Rozerem 8 mg).].
Hirai
Keisuke
K
Hirai_Keisuke@takeda.co.jp
Kato
Koki
K
Nishikawa
Hisao
H
Yukuhiro
Nobuhito
N
Nishiyama
Keiji
K
Miyamoto
Masaomi
M
D000818:Animals; D002908:Chronic Disease; D000242:Cyclic AMP / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007192:Indenes / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D044094:Receptors, Melatonin / Q000819:agonists*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D012894:Sleep Stages / Q000187:drug effects; D019966:Substance-Related Disorders; D013493:Suprachiasmatic Nucleus / Q000187:drug effects / Q000502:physiology
D007192:Indenes; D044094:Receptors, Melatonin; C495910:ramelteon; D000242:Cyclic AMP